Director and 10% owner Patrick W. Smith filed a Form 4 on November 20, 2026, disclosing the acquisition of 1,142,857 shares of Insight Molecular Diagnostics Inc. common stock on November 17, 2026, through an underwritten public offering at $1.75 per share, held indirectly via a trust.

Key Highlights

  • Reporting person: Patrick W. Smith, identified as a Director and 10% owner of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX)
  • Transaction date: November 17, 2026, with the form filed November 20, 2026
  • Shares acquired: 1,142,857 shares of common stock, no par value, with transaction code J
  • Price paid: $1.75 per share, described as the public offering price in an underwritten public offering
  • Beneficial ownership following transaction: 4,401,342 shares, held indirectly
  • Holding structure: Shares are directly held by Patrick W Smith The Smith Irrevocable Trust U/A DTD 05/01/2015, with Smith serving as trustee

Smith Trust Acquires Shares in Insight Molecular Diagnostics Public Offering

According to the Form 4 filing, Patrick W. Smith, who is listed as both a Director and a 10% owner of Insight Molecular Diagnostics Inc., acquired 1,142,857 shares of the company's common stock on November 17, 2026. The filing indicates the shares were purchased at the public offering price of $1.75 per share in an underwritten public offering of the issuer. The transaction is coded "J" in Table I of the filing.

The filing discloses that the acquired shares are not held directly by Smith in his personal name. Instead, according to footnote 2, the shares are "directly held by Patrick W Smith The Smith Irrevocable Trust U/A DTD 05/01/2015." The filing further states that "as the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust." As a result, the ownership form is reported as indirect.

Following the reported transaction, the filing states that Smith beneficially owns 4,401,342 shares of Insight Molecular Diagnostics common stock in total, on an indirect basis. No derivative securities transactions were reported in Table II of the filing. The form was signed by Patrick W. Smith and dated November 20, 2026.

What Was Disclosed

Patrick W. Smith, a Director and 10% owner of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX), disclosed the indirect acquisition of 1,142,857 shares at $1.75 each in an underwritten public offering on November 17, 2026, bringing his total indirect beneficial ownership to 4,401,342 shares.